Vertex Pharma (VRTX) Tops Q3 EPS by 48c, Lifts FY Guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $516.44 --0%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $3.56, $0.48 better than the analyst estimate of $3.08. Revenue for the quarter came in at $1.98 billion versus the consensus estimate of $1.86 billion.
GUIDANCE:
Vertex Pharma sees FY2021 revenue of $7.4-7.5 billion, versus the consensus of $7.32 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Cheetah Net Supply Chain Service Inc. (CTNT) Reports Q2 EPS of $0.04
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
